Dalbavancin OverviewDalbavancin (INN, trade names Dalvance in the US and Xydalba in Europe) is a novel second-generation lipoglycopeptide antibiotic. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA). Dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin. It possesses in vitro...
Read more Dalbavancin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dalbavancin
Recent Dalbavancin Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 500mg/vial
- Powder: 500mg/vial
- Powder, Lyophilized: 500mg
NDC Database Records for Dalbavancin: (1 result)Sorted by National Drug Code
- 57970-100 Dalvance 500 mg/25ml Intravenous Injection, Powder, for Solution by Durata Therapeutics Inc.
Other drugs which contain Dalbavancin or a similar ingredient: (1 result)
- Dalvance Dalbavancin Hydrochloride